Overall, these data suggest that IGF1R and IR expression at the plasma membrane could represent new biomarkers predicting tumour aggressiveness, as well as possible molecular markers useful to patients’ stratification for more individualized IGF1R-IR targeted therapies or for novel pharmacological approaches specifically targeting IRA isoform. The gene discussed is IGF1R; the disease is neoplasm.